| Dr Bruce Eric Genter, MD | |
|
422 Kenwood Rd, Huntingdon Valley, PA 19006-7812 | |
| (215) 450-7744 | |
| Not Available |
| Full Name | Dr Bruce Eric Genter |
|---|---|
| Gender | Male |
| Speciality | Plastic Surgery |
| Location | 422 Kenwood Rd, Huntingdon Valley, Pennsylvania |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1356544183 | NPI | - | NPPES |
| 0990778 | Medicaid | PA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208200000X | Plastic Surgery | MD030763-E (Pennsylvania) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Bruce Eric Genter, MD 422 Kenwood Rd, Huntingdon Valley, PA 19006-7812 Ph: (215) 450-7744 | Dr Bruce Eric Genter, MD 422 Kenwood Rd, Huntingdon Valley, PA 19006-7812 Ph: (215) 450-7744 |
News Archive
VION PHARMACEUTICALS, INC. announced today that it had filed a Special Protocol Assessment (SPA) with the U.S. Food and Drug Administration (FDA) related to a randomized Phase II/III trial of its oncology therapeutic Onrigin™ (laromustine) Injection in combination with low-dose Ara-C (LDAC) in elderly patients with newly diagnosed acute myeloid leukemia (AML). The primary objective for the Phase III part of this study is to determine if Onrigin™ plus LDAC improves overall survival compared with LDAC alone.
The Substance Abuse and Mental Health Services Administration (SAMHSA) will unveil the results of the latest (2010) National Survey on Drug Use and Health (NSDUH) at a press conference on Thursday, September 8.
BioTrends Research Group, Inc. recently published its TreatmentTrends: Renal Anemia in China report. This report is based on survey results from 150 nephrologists in clinical practice in China and qualitative interviews conducted with ten thought leaders in nephrology. The report examines the demographics of nephrology practice in China and focuses specifically on the management of renal anemia amongst dialysis and later stage chronic kidney disease patients.
An international research team including scientists from the University of Cologne have identified a new mechanism for the development of Parkinson's disease, which could prove to be the starting point for the development of a more targeted therapy.
› Verified 1 days ago
Carl Howard Manstein, MD Plastic Surgery Medicare: Accepting Medicare Assignments Practice Location: 821 Huntingdon Pike, Suite 120, Huntingdon Valley, PA 19006 Phone: 215-379-5700 Fax: 215-379-2520 |